Indevus Plans To Relaunch Valstar By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Company announces submission of an sNDA for bladder cancer treatment, which was pulled from the market in 2002 due to manufacturing issues.
You may also be interested in...
Indevus’ Valstar Is “Approvable” At FDA
Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.
Indevus’ Valstar Is “Approvable” At FDA
Agency seeks clarification of manufacturing validation protocols described in the firm’s sNDA for the bladder cancer treatment.
Indevus' Supprelin LA Clears FDA As Once-Yearly Treatment For Premature Puberty
Implant for treatment of central precocious puberty will launch this summer, targeted to pediatric endocrinologists.